Pay in 4 interest-free payments of $21.25 Learn more
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4
that converge on phosphorylating the α-subunit of initiation factor 2 (eIF2α )
Smiles: CN1CCN(CC1)C1=CC=C(C=N1)C1=CC(=C2C(=C1)N(C=C2C)C(C)C)C(=O)NCC1C(=O)NC(C)=CC=1C
orally bioavailable GPR40 agonist
SRI-011381 hydrochloride (10-75 mg/kg
AVL-292 Catalog No.:M11333-2 that converge on phosphorylating theSpebrutinib, also known as AVL 292 or CC 292, is an orally bioavailable, selective inhibitor of Brutons agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity. Upon administration, AVL 292 targets and covalently binds to BTK, thereby preventing its activity. By irreversibly inhibiting BTK, administration of this agent may lead to an inhibition of B cell receptor (BCR) signaling and may inhibit cell proliferation of B cell
US$ 160.20
US$ 1079.50
US$ 79.00
US$ 19.00
US$ 149.50
US$ 840.67
US$ 264.50
US$ 199.99
US$ 134.50
US$ 1499.50